Oral Treatment with Saccharomyces cerevisiae CNCM I-3856 Mitigates the Inflammatory Response Experimentally Induced by Salmonella enterica subsp. enterica Serovar Typhimurium in Mice
Probiotics and Antimicrobial Proteins · 2025
DOI: 10.1007/s12602-024-10359-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Probiotics and Antimicrobial Proteins, 2025. Verfasst von Lara L Campos und 11 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. Hauptthemen laut MEDLINE: Saccharomyces cerevisiae, Salmonella typhimurium, Probiotics, Salmonella Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
Salmonella spp. are intracellular, Gram-negative pathogens responsible for a range of diarrheal diseases, which can present either as self-limited (gastroenteritis) or as a systemic form (typhoid fever), characterizing a serious public health problem. In this study, we investigated the therapeutic effects of oral administration of Saccharomyces cerevisiae CNCM I-3856 in a murine model infected with Salmonella Typhimurium (ST). This yeast species has previously demonstrated the potential to support immune function and reduce inflammation and the ability to exert antimicrobial activity, which is important considering the increasing prevalence of antibiotic-resistant bacteria. Our findings revealed that mice infected with ST and only treated with sterile saline exhibited a higher mortality rate and body weight loss. In contrast, mice treated with I-3856 showed a notable reduction in these adverse outcomes. The yeast demonstrated a high capacity for co-aggregation with the pathogen. Furthermore, the significant amounts of yeast found in the feces of treated mice suggest that intestinal colonization was effective, which was associated with several beneficial effects, including reduced intestinal permeability, which likely limits bacterial translocation to extraintestinal organs. Additionally, the administration of I-3856 reduced levels of sIgA and resulted in a decrease in the recruitment of neutrophils and eosinophils to infection sites, indicating a modulation of the inflammatory response. Histological analyses showed attenuated liver and intestinal lesions in the yeast-treated mice, corroborating the protective effects of the yeast. In conclusion, the results suggest that S. cerevisiae CNCM I-3856 has the potential to control the inflammatory response experimentally induced by S. Typhimurium when administered to mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
- Departamento de Patologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
- Departamento de Ciências Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brazil.
- Departamento de Análises Clínicas E Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
- Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. flaviano@icb.ufmg.br.
Förderung
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Campos, L. L., Oliveira, S. R. M., Amaral, M. N. S., Gallotti, B., Oliveira, A. F., Arantes, R. M. E., Ribeiro-Souza, S., Vital, K. D., Fernandes, S. O. A., Cardoso, V. N., Nicoli, J. R., & Martins, F. S. (2025). Oral Treatment with Saccharomyces cerevisiae CNCM I-3856 Mitigates the Inflammatory Response Experimentally Induced by Salmonella enterica subsp. enterica Serovar Typhimurium in Mice. Probiotics and Antimicrobial Proteins. https://doi.org/10.1007/s12602-024-10359-4
Vancouver
Campos LL, Oliveira SRM, Amaral MNS, Gallotti B, Oliveira AF, Arantes RME, et al. Oral Treatment with Saccharomyces cerevisiae CNCM I-3856 Mitigates the Inflammatory Response Experimentally Induced by Salmonella enterica subsp. enterica Serovar Typhimurium in Mice. Probiotics and Antimicrobial Proteins. 2025. doi:10.1007/s12602-024-10359-4
BibTeX
@article{Campos2025,
author = {Campos, Lara L and Oliveira, Samantha R M and Amaral, Maisa N S and Gallotti, Bruno and Oliveira, Aline F and Arantes, Rosa M E and Ribeiro-Souza, Samantha and Vital, Katia D and Fernandes, Simone O A and Cardoso, Valbert N and Nicoli, Jacques R and Martins, Flaviano S},
title = {Oral Treatment with Saccharomyces cerevisiae CNCM I-3856 Mitigates the Inflammatory Response Experimentally Induced by Salmonella enterica subsp. enterica Serovar Typhimurium in Mice},
journal = {Probiotics and Antimicrobial Proteins},
year = {2025},
doi = {10.1007/s12602-024-10359-4}
}
EUVIMED